ATS Breathe Easy - Understanding HER2-Positive Lung Cancer, from Genetic Testing to Targeted Treatment copertina

ATS Breathe Easy - Understanding HER2-Positive Lung Cancer, from Genetic Testing to Targeted Treatment

ATS Breathe Easy - Understanding HER2-Positive Lung Cancer, from Genetic Testing to Targeted Treatment

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.

While most people are familiar with HER2 in regards to breast cancer, there are HER2 mutations in lung cancer. On this episode of the ATS Breathe Easy podcast, host Patti Tripathi explores HER2-mutant non-small cell lung cancer (NSCLC), an uncommon but increasingly treatable form of lung cancer. Oncologist Christine Lovly, MD, PhD, City of Hope, explains the rapidly evolving science behind HER2 testing and targeted therapies, while patient Nicole Field shares her experience living with stage IV HER2-mutant lung cancer.

For more resources, check out these organizations:

LUNGevity Foundation: https://www.lungevity.org/
International Cancer Advocacy Network: https://askican.org/
Rexanna’s Foundation: https://rexannasfoundation.org/

adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione